Your browser doesn't support javascript.
loading
Buprenorphine for Chronic Pain Management: a Narrative Review.
Vu, Peter D; Bansal, Vishal; Chitneni, Ahish; Robinson, Christopher L; Viswanath, Omar; Urits, Ivan; Kaye, Alan D; Nguyen, Anvinh; Govindaraj, Ranganathan; Chen, Grant H; Hasoon, Jamal.
Afiliação
  • Vu PD; Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
  • Bansal V; Department of Physical Medicine and Rehabilitation, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
  • Chitneni A; Department of Rehabilitation and Regenerative Medicine, New York-Presbyterian Hospital - Columbia and Cornell, New York, NY, USA.
  • Robinson CL; Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Viswanath O; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Urits I; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Kaye AD; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Nguyen A; Department of Anesthesiology, Baylor College of Medicine, Houston, TX, USA.
  • Govindaraj R; Department of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
  • Chen GH; Department of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
  • Hasoon J; Department of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA. Jamal.J.Hasoon@uth.tmc.edu.
Curr Pain Headache Rep ; 27(12): 811-820, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37897592
PURPOSE OF REVIEW: The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine. RECENT FINDINGS: Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions. Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Buprenorfina / Dor Aguda / Dor Crônica / Transtornos Relacionados ao Uso de Opioides Limite: Humans Idioma: En Revista: Curr Pain Headache Rep Assunto da revista: FISIOLOGIA / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Buprenorfina / Dor Aguda / Dor Crônica / Transtornos Relacionados ao Uso de Opioides Limite: Humans Idioma: En Revista: Curr Pain Headache Rep Assunto da revista: FISIOLOGIA / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos